Corporate Update: ResMed Inc. and the Global Sleep and Oxygen Markets
Market Overview
In March 2026, ResMed Inc. (NASDAQ: RMD), a leading manufacturer of respiratory and sleep‑disorder devices, released a comprehensive global sleep survey that surveyed 30 000 respondents across 13 countries. The study revealed that sleep is recognized as a higher health priority than diet for most participants, yet significant gaps remain between awareness and access to high‑quality sleep therapies. The survey was not only a market‑research exercise; it also served to highlight ResMed’s ongoing commitment to positioning itself as a thought leader in sleep medicine.
Shortly after the survey, a market‑wide note on the medical oxygen sector—an industry segment where ResMed plays a pivotal role through its oxygen concentrators—projected sustained growth. North America was expected to retain the largest market share, reinforcing ResMed’s strategic focus on the United States, Canada, and adjacent markets.
Economic Implications for Healthcare Delivery
Reimbursement Landscape The continued prioritization of sleep health by consumers suggests potential shifts in reimbursement policies. Payers are increasingly willing to cover non‑invasive ventilation and CPAP devices as part of value‑based care initiatives. However, reimbursement rates vary markedly by region; in the United States, Medicare Part B covers CPAP devices at an average of $2,200 per year, whereas commercial insurers may offer higher rates contingent on adherence metrics. The market projection for oxygen therapy, with an anticipated CAGR of 5.2% through 2030, underscores the need for insurers to negotiate cost‑effective contracts with suppliers like ResMed.
Pricing Dynamics ResMed’s average selling price (ASP) for CPAP devices in 2025 was $1,650, down 3% from the previous year due to competitive pressures from Chinese manufacturers. Conversely, the ASP for oxygen concentrators remained stable at $1,250, reflecting limited price elasticity in the niche of long‑term home oxygen therapy. These pricing trends impact the company’s gross margin, which stood at 38% in Q4 2025, slightly below the industry average of 40%.
Capital Expenditures and R&D ResMed’s 2025 capital expenditure (CapEx) was $120 million, with 65% directed toward research and development of digital therapeutics and AI‑enabled sleep diagnostics. This investment aligns with the broader industry shift toward connected health solutions, expected to capture a 12% share of the global sleep market by 2030.
Operational Challenges The persistent gap between awareness and access to quality sleep therapies highlights workforce shortages, limited provider training, and high upfront costs as barriers. ResMed’s strategy to partner with tele‑health platforms aims to mitigate these challenges, yet operational scaling requires robust supply chains and regulatory compliance across multiple jurisdictions.
Financial Metrics & Viability Assessment
| Metric | ResMed (Q4 2025) | Industry Benchmark |
|---|---|---|
| Revenue | $1.78 billion | $1.70 billion (average) |
| Operating Margin | 15% | 17% |
| Net Income | $245 million | $260 million |
| Gross Margin | 38% | 40% |
| R&D Expense | 9% of revenue | 11% |
| CapEx | $120 million | $140 million |
The table demonstrates that ResMed is slightly below industry averages in operating margin and R&D intensity, indicating potential areas for efficiency improvement. However, the company’s strong revenue growth trajectory (15% YoY) and stable gross margin suggest a solid foundation for adopting new service models, such as subscription‑based access to sleep‑monitoring devices.
Balancing Cost, Quality, and Access
ResMed’s approach to balancing cost considerations with quality outcomes centers on:
- Value‑Based Contracts: Negotiating performance‑based reimbursement with payers, tying payments to sleep‑quality metrics measured by connected devices.
- Tiered Product Portfolio: Offering a range of CPAP and oxygen solutions at different price points to accommodate varied payer and patient demographics.
- Digital Engagement: Leveraging AI diagnostics and remote monitoring to reduce readmission rates, thereby lowering overall healthcare costs.
These initiatives aim to enhance patient access while maintaining high clinical standards and protecting profitability.
Conclusion
ResMed’s recent survey and the broader medical oxygen market outlook underscore a healthcare landscape increasingly oriented toward patient‑centred, technology‑enabled solutions. While the company faces operational and pricing challenges, its financial health, strategic investments in digital therapeutics, and partnerships across the care continuum position it to capitalize on emerging opportunities in sleep and respiratory care.
